# Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine

> **NCT01357915** · NA · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 47 (actual)

## Conditions studied

- Infections, Cytomegalovirus

## Interventions

- **PROCEDURE:** Blood sampling
- **BIOLOGICAL:** GSK149203A

## Key facts

- **NCT ID:** NCT01357915
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-24
- **Primary completion:** 2012-09-13
- **Final completion:** 2012-09-13
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357915, "Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01357915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*